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The prevalence of chronic respiratory disorders has
been increasing steadily over the past several years
and currently constitutes a serious public health
problem. Chronic respiratory disorders (including
lung cancer) represent worldwide the second most
important cause of mortality and their frequency
and diffusion are probably far greater than realized,
given that they are often underdiagnosed and mis-
diagnosed. As a matter of fact, many patients are
not diagnosed until the chronic respiratory disease
is severe enough to prevent normal daily activities.
Underdiagnosis has not only an epidemiological
relevance, but also implies clinical consequences:
as little attention is paid to respiratory diseases by
the individual and the community, those affected
receive late and non-optimal treatment.
Furthermore, insufficient consideration is given to
the general and specialist health services that
should take care of chronic respiratory patients [1-
2]. The future trend is for a further increase, though
differentiated for the individual disorders. Chronic
obstructive pulmonary disease (COPD) in particular
is estimated to become the third leading cause of
death worldwide by the year 2020 [3]. At present,
most people are not diagnosed until they are in
their late 50s when their respiratory lung function
has already begun to decline in a clinically signifi-
cant way [4]. The high level of
underdiagnosis/undertreatment or misdiagnosis/
mistreatment is evidence of the generally inade-
quate standards of care - a problem even in devel-
oped countries - at all levels of intervention, from
prevention (that is inadequate) to long-term man-
agement (that is inappropriate) [5,6].
Given the increasing social impact of COPD, the
conference on which this report is based (“COPD a
social disease: inappropriateness and pharmaco-
economics. The role of the specialist: present and
future”, held in Venice, Italy, April 21-22, 2010) was
in tune with the goals and recommendations of
GARD, the Global Alliance against chronic
Respiratory Diseases of the World Health
Organisation. GARD has formulated the following
working recommendations: 
1. to develop national programs of prevention and
control of chronic respiratory diseases (CRDs),
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9 starting with health education campaigns and a
better knowledge of epidemiology, impact, and
relative risk factors; 
2. to provide training and continuing education on
prevention and treatment of CRDs, disseminating
the existing guidelines; and 
3. to facilitate access to essential treatments and
favour adherence to long term treatment, includ-
ing drug treatment and pulmonary rehabilitation,
particularly amongst disadvantaged sectors of the
population.
PREVENTION
The reduction of the social and individual impact of
chronic respiratory diseases is based not only on
early diagnosis and treatment, but also on the mod-
ification of environmental and social factors. Today,
many risk factors have been identified, such as
tobacco smoke, allergens, occupational agents, and
indoor and outdoor air pollution, the prevention of
which will have a significant impact on morbidity
and mortality.
A wide array of lifestyle modifications can help pre-
vent COPD, including: smoking cessation, meas-
ures to avoid allergens and respiratory irritants, pre-
vention of infections, maintaining a balanced nutri-
tion and hydration, avoiding extreme environmen-
tal conditions, weight control, and physical exercise
to increase muscle tone. Consolidated data exist
only for active and secondhand cigarette smoking,
occupational exposure and outdoor and indoor air
pollution [7].
Smoking is the leading cause of COPD: 80 to 90%
of subjects diagnosed as COPD are long-term
smokers. Secondhand smoke exposure and occupa-
tional exposure may also influence the develop-
ment and the progression of the disease [7,8]. The
burden of non smoking-related COPD is, however,
much higher than previously thought, with an esti-
mated 25-45% of patients with COPD having never
smoked. 
A systematic epidemiological review by the
American Thoracic Society showed that about 15%
of COPD cases might be attributable to exposure to
toxic gases in the workplace, grain dust in farms,
and dust and fumes in factories [8]. 
Exposure to indoor and outdoor air pollutants is a
major contributing factor to the increased morbidi-
ty, healthcare resources utilization and higher mor-
tality among patients with COPD, but there are few
studies on whether air pollution is a key factor in the
development of this disease [9]. Indeed, the greatest
risk factor for COPD globally might be exposure to
biomass smoke, since about half the world’s popula-
tion (3 billion people) are exposed to smoke from
biomass fuel compared with 1.01 billion who smoke
tobacco. Byproducts of oxidative stress found in air
pollutants (ozone, sulfur oxides, carbon monoxide,
nitrogen oxides, and particulate matter) are common
initiators or promoters of the damage produced in
chronic diseases of the airways.
Strong evidence exists also for infections as a trigger
of COPD exacerbations. Avoiding respiratory ill-
nesses, such as influenza and pneumonia, can
decrease the risk of COPD worsening [9].
Vaccinations can prevent some of the infections
that cause COPD exacerbations and should be
administered to all patients with COPD, although
clinical trial data on this are limited. In a large
cohort of COPD patients admitted to Italian hospi-
tals for an exacerbation, the percentage of subjects
who had been vaccinated against influenza and
pneumococcal infections was only 58% and 13%
respectively [6].
More solid data on risk factors for COPD develop-
ment, progression and exacerbation are required in
order to implement cost-effective prevention and
management strategies.
DIAGNOSIS
The diagnosis of COPD is conventionally based on
spirometry in the presence of a risk factor such as
smoking or occupational exposure [11]. But the
importance of adding medical history data to
spirometry, stressing the importance of persistent
cough and phlegm in support of an earlier diagnosis
of COPD in family practice [12], must be stressed
as there is still a considerable underpresentation
and underdiagnosis of COPD.
For interpretation of the spirometry, the GOLD
(Global Initiative for Chronic Obstructive Lung
Disease) Committee suggested the use of a fixed
FEV1/FVC cut-off of 0.70 instead of the more appro-
priate statistically defined lower limit of normal
(LLN), since the fixed ratio is easy to remember and
apply and not dependent on the choice of a refer-
ence equation. According to a number of recent
papers, however, the fixed cut-off of 0.70 signifi-
cantly overestimates airflow obstruction in older
people, leading to misuse of resources, and individ-
ual and societal harm [13-15], while it under -
estimates airflow obstruction among young adults,
leading to a missed opportunity for an early diagno-
sis of COPD in patients who are more likely to ben-
efit from intervention [13]. Since diagnostic confu-
sion between COPD and asthma is common, bron-
chodilation performed after spirometry may help to
reduce the chance of misclassification [11].
The complexity and heterogeneity of the disorders
encompassed by the term COPD with the overlap
of different phenotypes has recently led to the fol-
lowing recommendations: i) to develop a new tax-
onomy in order to better define the disorders of air-
ways obstruction and, consequently, ii) to make
clinical assessment more multidimensional [16].
Besides FEV1/FVC, lung volumes should always be
included in the diagnosis of COPD as evaluation 
of hyperinflation is an important criterion for the
phenotyping of COPD patients.
TREATMENT
Over the latest two decades, in COPD treatment a
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nihilistic attitude based on smoking cessation as the
only possible treatment, to the current opinion -
thanks to several large trials that examined not only
pharmacological agents but also pulmonary reha-
bilitation and lung volume reduction surgery - that
COPD is not only preventable but also treatable
[11,17]. Unfortunately, the value of the findings
from therapeutic trials is limited as the study popu-
lations were highly selective. As a matter of fact,
patients were included only if they had COPD and
were free of concomitant morbidities that might
impact negatively on the trial outcomes. In the real
world, however, COPD patients are frequently
afflicted by multiple comorbidities, such as heart
disease, osteoporosis, peripheral muscle weakness
and dysfunction, anemia, depression, anxiety and
lung cancer, and more frequently so than the gener-
al population [18].
The pathophysiological hallmark of COPD is vari-
able airflow obstruction resulting in pulmonary
hyperinflation. Progressive decline in lung function
leads COPD patients to experience in the course of
time significant limitation in their daily life activi-
ties, including dyspnea, limited exercise capacity,
frequent exacerbations and hospitalizations. 
Over the last few years, pharmacotherapy studies
have demonstrated that bronchodilators can reduce
dynamic hyperinflation, increase inspiratory capac-
ity (by reducing the functional residual capacity),
decrease the work of breathing, and improve venti-
latory capacity during activity and formal exercise
testing. At a clinical level, bronchodilators have
been shown to improve dyspnea, decrease exacer-
bations, ameliorate health-related quality of life
(HRQoL), and decrease mortality [11,17].
Clinical studies of long-acting bronchodilators,
long-acting β2-agonists (LABA) such as formoterol,
salmeterol and more recently (though to date less
supported by data) indacaterol, and long-acting
anti-muscarinic agents (e.g. tiotropium) showed sig-
nificant improvement in trough peak FEV1 (range,
0.1-0.3 L) and average FEV1 (range, 0.1-0.25 L)
compared to a decline in placebo-treated patients
(short-acting β2-agonists, and/or ipratropium)
[19,20]. 
Clinical studies evaluating the use of combination
of tiotropium and LABA showed that there is a syn-
ergistic effect of the combination therapy and fur-
ther improvement in lung function. This combina-
tion therapy would be suitable for patients with
severe disease [21]. 
The sustained improvement in lung function seen in
these studies suggests that long acting bronchodila-
tors may slow down the decline in lung function
over time and subsequently change the clinical
course of the disease.
Clinical studies using triple therapy - tiotropium and
a fixed combination of LABA and inhaled corticos-
teroid (ICS) – have demonstrated an enhanced
improvement in lung function, and reduction of
exacerbations as compared with individual agents
alone [22]. 
Several of these studies also showed improvements
in morning and daytime symptoms, night-time
arousal, reliever use, and HRQoL. In COPD
patients with severe and very severe disease, triple
therapy is highly effective.
An important issue is whether regular treatment
with long-acting bronchodilators and/or the combi-
nation of LABA/ICS should be initiated at an earlier
stage of the disease. Reports of a sub-analysis of the
TORCH and UPLIFT studies show that patients with
moderate disease would benefit from these thera-
pies. These studies showed significant increase in
trough FEV1, peak FEV1, dyspnea score, and
HRQoL. Notably, patients also had a significant
reduction in exacerbations [20].
The recent analysis of the large tiotropium database
and the findings of the prospective UPLIFT study
indicate a reduced risk for mortality from cardiovas-
cular events and even overall mortality in patients
receiving tiotropium. The mechanism by which
tiotropium may reduce these events and improve
survival could be associated with the significant
reductions in exacerbations and hospitalizations
observed, but conclusive evidence is lacking. In the
pooled analysis of 30 trials, tiotropium treatment
also resulted in significant reductions in serious car-
diac adverse events [23].
In the TORCH study, the patients randomized to
LABA alone had the lowest rate of cardiovascular
death. A range of predictable factors increased the
cardiovascular event rate, including: older age, a
history of previous cardiac disease, and worse lung
function. None of these factors interacted with
treatment to identify a specific ‘at risk’ group [24].
According to recent controlled randomized trials
the risk of pneumonia is higher in patients receiving
inhaled fluticasone. In the TORCH study, patients
receiving at least 1,000 mcg/day of fluticasone pro-
pionate equivalent, compared with non-users of
inhaled corticosteroids within the past year, had a
rate ratio for pneumonia hospitalization of 2.25
(95% CI 2.07– 2.44). The TORCH trial showed no
difference in pneumonia mortality between patients
receiving inhaled corticosteroids and those not
receiving them [25]. A new class of drugs is that of
the selective phospho - diesterase-4 inhibitors. The
most promising agent, roflumilast, taken orally once
daily targets the airways inflammation that is a hall-
mark of the disease. Participants in different 6- and
12-month studies who received roflumilast alone or
in combination with salmeterol and/or tiotropium
experienced a significant improvement in lung
function, quality of life and reduction in exacerba-
tions. The two most frequent adverse events in the
roflumilast group were diarrhea and weight loss,
mild in nature but disturbing in a long-term treat-
ment [26]. This medication is on the way for
approval by the regulatory agencies.
FOLLOW UP
Exacerbations of COPD are a frequent cause at fol-
low up of emergency visits and hospitalizations,






























9 healthcare systems. An exacerbation of COPD is
defined as a change in the patient’s baseline dys -
pnea, cough, and sputum beyond day-to-day varia-
tions, that is acute in onset and may warrant a
change in regular medication [11]. 
The management of patients with an exacerbation
shows very large variability among the different set-
tings and reveals the inadequate standards of care
[6]. This applies even more so to the follow up
modalities after hospitalization, which aim to opti-
mize care and reduce the risk of a relapse (the
recurrence of which is greatest within the first few
weeks of the initial event) [27,28]. 
A number of risk factors have been identified that
facilitate the occurrence of a new exacerbation,
including: number of previous exacerbations, previ-
ous hospitalizations, use of long term oxygen thera-
py (LTOT), poor lung function, absence of a primary
caregiver and choice of pharmacological therapy
[6,29]. 
Concerning follow up, a number of points need to
be better investigated, such as appropriate function-
al diagnosis and severity stratification (e.g. spiro -
metry is largely underused) [6], the potential benefit
of home monitoring and of noninvasive ventilation
as well as the value of LTOT in borderline respirato-
ry failure, the effectiveness of self-management pro-
grams, and of early rehabilitation (PR). 
Available data suggest that an early PR intervention
should be included in the follow up program. PR
after an exacerbation reduces the hospitalization
rate and improves exercise capacity and quality of
life [30]. Therefore, efforts should be made to
improve the availability of PR for COPD patients in
different healthcare settings. In fact, a large multi-
centric Italian study demonstrated that only 14.5%
of COPD patients admitted to hospital for an exac-
erbation were offered PR [6].
Long-term oxygen therapy (LTOT)
Oxygen therapy is an essential treatment in the care
of COPD patients with chronic respiratory failure.
The evidence supporting the large use of LTOT and
the indications reported in international documents
are based on two landmark prospective, random-
ized clinical trials - NOTT and MRC - published
about 30 years ago [31,32]. These studies showed
that survival improves in stable COPD patients who
receive LTOT for more than 15 hours/day in the
long term. The effectiveness of LTOT in improving
survival has been documented only in COPD
patients with severe chronic hypoxemia (PaO2 < 55
mm Hg (7.3 kPa) or PaO2 ranging from 56 to 59 mm
Hg (7.4-7.8 kPa) in the presence of cor pulmonale,
or hematocrit > 55%).
The LTOT indications (based on NOTT and MRC)
were established in a very selected and limited
number of patients that are unlikely to represent the
heterogeneity of the real COPD population. These
recommendations have been subsequently extend-
ed, albeit without solid evidence, to COPD patients
with moderate hypoxemia (55 < PaO2 < 65 mm
Hg), and to patients with decreased oxygen satura-
tion (SaO2 < 90%) during exercise or sleep
[11,17,33]. Comorbidities are likely to affect both
prognosis and health outcomes in COPD patients
but clinical practice guidelines do not provide ade-
quate guidance for patients on LTOT with complex
chronic diseases.
Disease stability before prescribing LTOT should be
mandatory, but quite commonly COPD patients are
prescribed oxygen at home simply because they are
still hypoxemic at discharge from hospital after an
exacerbation, despite an absence of data to support
the short-term benefits of oxygen therapy. Actually,
after an exacerbation, up to 38% of COPD patients
improve peripheral blood oxygenation to PaO2 lev-
els above those qualifying in the selection criteria
for LTOT, simply by optimizing medical therapy
[34]. A reassessment of the indication for LTOT after
3 months of clinical stability could significantly
reduce the number of patients eligible for LTOT
soon after an episode of exacerbation [11,17].
Given the increasing numbers of patients receiving
long-term supplemental oxygen, a critical review of
the current indications for LTOT is needed, particu-
larly for COPD patients with comorbidities, mild-
moderate hypoxemia, exercise and sleep desatura-
tion, so that LTOT is prescribed only for patients in
whom there is a reasonable expectation of clinical
benefit.
Non-pharmacological therapies
The National Emphysema Trial (NETT) represents
the first case in which a surgical procedure in
COPD was subjected to a randomized trail using a
medical comparator, in this case optimal medical
therapy and pulmonary rehabilitation. In the base-
line evaluation and follow up of the patients includ-
ed in NETT, a very low FEV1 and diffusion capacity
for carbon monoxide (DLCO) were associated with
a very poor outcome [35]. These observations had
important consequences in the clinical practice, in
terms of defining which patients are most appropri-
ate candidates for lung volume reduction proce-
dures.
Several trials have emphasized the beneficial con-
sequences of pulmonary rehabilitation with very lit-
tle evidence regarding side effects. The only draw-
back related to negative outcome is that of patients
who do not want to participate in rehabilitation or
who do not complete the program. The percentage
of patients who do not join programs is very high,
around 60%, and out of those who do join close to
30% fail to complete the program. Very little has
been done to better characterize those patients and
evaluate the factors that led to their lack of compli-
ance and uptake [36].
Pharmacoeconomic issues
The total cost of respiratory diseases in Europe is
more than €100 billion per year. COPD contributes
to at least half of this figure, followed by asthma,
pneumonia, lung cancer and tuberculosis. In gener-
al, inpatient hospital services represent 17.5% of
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drugs 6.6%, costs related to mortality and rehabili-
tation 19.6%, and lost work days 47.4% [37].
The cost of pharmacological treatment for COPD is
steadily increasing across all European countries,
this being due, on the one hand, to expensive, new
hospital treatments with biological drugs and med-
ications for cancer, and, on the other, to an expan-
sion of the subpopulation of elderly people and,
consequently, of the number of people with com-
mon chronic diseases including COPD. Around the
end of the last century there was a growing interest
in pharmacoeconomic issues corresponding to the
overall need for “accountability”, and the econom-
ic evaluation of working strategies progressively
became the crucial point for decision makers in
allocating the ever diminishing healthcare
resources. 
Although pharmacoeconomic data are not easy to
compare among the different national health sys-
tems, the following examples will reveal some
points in common, in particular: i) the very high
absolute and relative burden of COPD, despite its
substantial underdiagnosis; ii) the progressive
increase of costs with increasing disease severity,
the largest share of costs being due to exacerbations
and hospitalizations; iii) the high costs due to LTOT
among therapies; and iv) the inadequate coverage
provided to the citizen for drug expenses.
THE PHARMACOECONOMIC SITUATION 
IN NORTH AMERICA
Canada
According to the BOLD survey the prevalence of
COPD in subjects aged 40 years or older in Canada
is 11.1% (Stage I), 7.3% (Stage II) and 0.9% (Stage
III-IV) or about 3.3 million, considerably higher
than the official estimate of 750,000 Canadians suf-
fering from COPD, based on reported physician
diagnosis [38]. As in other countries, there is a very
large undiagnosed COPD population in Canada
[5]. Despite this, respiratory diseases rank fourth in
Canada in terms of the proportion of healthcare
costs [38].
Primary care providers (PCP) are usually the first
point of care for patients with COPD and the major-
ity of physicians (PCPs and specialists) are paid on
a fee-for-service basis. Consultation by specialists is
generally arranged through a PCP, because services
for non-referred patients are paid at a lower rate. As
for costs of delivering COPD care, the Canadian
RUSIC study [39] estimated that exacerbations of
COPD requiring a medication change plus a visit to
an outpatient facility including an emergency
department had a mean cost of $641 (CAN 2006 $),
whereas the mean cost of an exacerbation requiring
hospitalization was $9,557. In 2003, the
Confronting COPD Survey estimated that the annu-
al direct cost of COPD care, including laboratory
tests and visits to PCPs and specialists, was almost
$2000 per patient, with about half of the costs due
to hospitalization [40]. The estimated economic
burden of COPD through work loss was $1,198 per
patient, giving an annual societal cost of $3,195 per
patient. Costs increased in direct proportion to the
severity of COPD as measured either by FEV1 or
MRC dyspnea score.
There is no universal drug plan in Canada, and pri-
vate payments are required for many citizens for
medications, with differences from province to
province. Thus while the Canadian [5] and other
[11] clinical practice guidelines for COPD recom-
mend a long-acting anticholinergic bronchodilator
or a LABA as first line treatment and combinations
of long-acting bronchodilators with or without ICS
for more advanced disease, these restrictive provin-
cial formularies act as barriers to physicians who
wish to follow guidelines.
A survey of Canadian PCP practice patterns in
COPD in the provinces of Ontario and Quebec
(CAGE study) observed that pharmacologic treat-
ment that matched Canadian guidelines was pres-
ent in only 34% of practices [41]. Non-prescription
of long-acting bronchodilators for patients with
moderate and severe COPD occurred in 27% and
21% of cases respectively and prescription of two
long-acting bronchodilators for advanced COPD
occurred only in 49% of subjects.
A cost effectiveness analysis of the Canadian [5]
and GOLD [11] recommendations for COPD phar-
macotherapy was based on the results from the
Canadian OPTIMAL trial [42,43]. This study
demonstrated that triple therapy with tiotropium
plus fluticasone plus salmeterol was superior to
tiotropium plus salmeterol, or to tiotropium alone in
terms of lung function, frequency of exacerbations
requiring hospitalization and quality of life. 
The cost effectiveness analysis demonstrated that
the incremental cost per exacerbation avoided with
tiotropium plus fluticasone plus salmeterol was
$6,510 (CAN) and the incremental cost per quality
adjusted life year (QALY) gained was $243,180
(CAN) [42]. The authors concluded that neither
tiotropium plus fluticasone plus salmeterol nor
tiotropium plus salmeterol seem economically
attractive alternatives compared to monotherapy
with tiotropium for moderate-to-severe COPD, in
the context of an acceptable societal cost per QALY
gained and per exacerbation avoided [42].
Among non-pharmacologic therapies, pulmonary
rehabilitation has undergone cost/benefit analysis
in the Canadian context [44]. An economic analysis
of a 2-month inpatient followed by 4-month out -
patient program estimated a cost of $11,597 (CAN)
to achieve clinically significant outcomes in dysp-
nea, emotional function, and mastery, with more
than 90% of the costs being due to the inpatient
phase of the program [44]. A more recent study
demonstrated potential cost savings resulting from
fewer hospitalizations for COPD patients success-
fully completing a pulmonary rehabilitation pro-
gram [45]. It must also be emphasized the value
and potential cost-effectiveness of developing
smaller outpatient and home-based rehabilitation
programs [46].






























9 cant gains in COPD healthcare utilization have
been realized by collaborative self-management
education interventions [47]. A Canadian random-
ized controlled trial comparing case manager-
 driven self-management education versus usual
care demonstrated a 40% reduction in the need for
COPD patients to access healthcare resources
including hospitalizations, emergency department
visits and unscheduled clinic visits [48]. 
In many provinces a restructuring of primary care
into multidisciplinary teams is in progress; these are
given financial incentives to provide comprehen-
sive care including certified respiratory educators-
facilitated self-management education [49].
United States
COPD affects about 20-24 million United States cit-
izens, being the fourth leading cause of death in the
U.S. with more than 125,000 deaths annually. In
2010, the direct healthcare costs of COPD are pro-
jected to total $29.5 billion [50]. Of these costs,
$13.2 billion are due to hospital care, $5.5 billion
are physician costs, $5.8 billion are outpatient pre-
scription drug costs, $1.3 billion are home health-
care costs, and $3.7 billion are nursing home care.
Long-term oxygen therapy costs Medicare more
than $2 billion per year for COPD and the cost is
growing by 12-18% per year [51]. In addition, there
are $20.4 billion in indirect costs due to lost pro-
ductivity from death and disability.
The pharmacoeconomic evaluations of COPD have
recently been critically reviewed with generally
concordant results, despite a number of method-
ologic flaws [52].
Three older retrospective analyses have shown that
the anticholinergic bronchodilator ipratropium in
early stage COPD and a combination anticholiner-
gic/β-agonist in more advanced COPD are associat-
ed with lower overall healthcare costs, largely
because of a reduction in exacerbations requiring
hospital care [53]. 
Another retrospective analysis compared costs of
COPD treatment with ipratropium versus theo-
phylline [54]. The overall healthcare costs were
28% lower in those patients treated with ipratropi-
um, mainly because of a reduction in exacerba-
tions. An analysis of healthcare costs from a health
maintenance organization database showed that
monotherapy with ipratropium was associated with
a reduction in healthcare costs compared to
monotherapy with either a β-agonist, inhaled
steroid, or theophylline in the first six months fol-
lowing COPD diagnosis. Subsequent treatment
with combination therapy with ipratropium and a 
β-agonist was also lower in terms of healthcare
costs than other therapy groups [55]. These observa-
tional studies were supported by an economic
analysis of two clinical trials of ipratropium/
albuterol combination compared to ipratropium or
albuterol alone [56]. Both of the ipratropium arms
of the study indicated lower direct healthcare costs
than albuterol alone. Again, the main component of
the reduced expenditures was related to fewer
exacerbations and fewer hospitalizations.
Long-acting β-agonists (LABA) as monotherapy are
effective in reducing COPD exacerbations com-
pared to placebo, and this translates into a reduc-
tion in healthcare expenditures, although studies
did not provide a comparison to other bronchodila-
tor monotherapies [57]. Monotherapy with an
inhaled corticosteroid, fluticasone, assessed in a
placebo controlled trial was found to be associated
with a reduction in both direct healthcare expendi-
tures as well as indirect healthcare costs from days
of incapacitation [58]. A clinical trial comparing the
long-acting anticholinergic tiotropium to ipratropi-
um demonstrated a 26% reduction in exacerbations
and 46% reduction in hospitalizations associated
with tiotropium.
The cost-effectiveness of ICS was greater in the most
severely impaired individuals [59].
Three economic analyses of the TORCH trial have
been published. TORCH compared salmeterol-fluti-
casone combinations (SFC) to the individual com-
ponents and placebo. 
In one study using the United States cost structure,
salmeterol was the most cost-effective drug 
($20,797/QALY) and SFC was second most cost-
effective ($33,865/QALY). Fluticasone alone, which
did not improve survival in TORCH, was not con-
sidered cost-effective [60]. 
A similar Markov-chain analysis of the TORCH trial,
using different cost assumptions, found that SFC
was the most cost-effective ($52,046/QALY), fol-
lowed by salmeterol monotherapy ($56,519/QALY)
and fluticasone monotherapy ($56,519) [61]. 
In a third analysis of TORCH, using a multinational
approach to cost structure, SFC was also found to
be most cost effective, compared to salmeterol
monotherapy and fluticasone monotherapy. The
cost-effectiveness was considerably lower for SFC
in the United States ($77,100/QALY) than in
Western Europe ($24,200/QALY) [62]. 
Analysis of a Medicare database using actual
healthcare expenditures compared the costs of ini-
tial maintenance therapy for COPD using SFC, ipra-
tropium monotherapy, ipratropium-albuterol
monotherapy, and tiotropium. In this retrospective
comparison, SFC was associated with slightly more
cost savings than tiotropium ($110/year), and iprat-
ropium-albuterol ($295/year), but was substantially




In Spain, the prevalence of COPD was 9% in adults
between 40 and 70 years of age in 1999, although
only 22% were diagnosed. In another population-
based study performed ten years later, the observed
prevalence was 10.2% and the underdiagnosis per-
sisted, with only 27% of individuals with COPD
having a previous diagnosis of the disease [64].
Top-down estimates have been carried out on the
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and epidemiological data. These studies reported
figures of around €800 million annually in 1994
including both direct and indirect costs. In a micro-
economic study performed in 1,510 patients with
ambulatory COPD followed over one year (bottom-
up), the average annual cost per patient was 
$1,876. From this study the approximate direct
annual cost generated by COPD in Spain may be
calculated from the prevalence. In the IBERPOC
population-based epidemiological study, the preva-
lence of COPD was estimated to be 9% in the 40-
69 year age group, of which only 22% were diag-
nosed and received treatment of some kind.
Therefore, a total of 270,000 subjects would be diag-
nosed and treated for COPD multiplied by the annu-
al average obtaining a total of $506.52 million annu-
ally in direct healthcare costs generated by COPD.
In a top-down calculation the hospital costs
accounted for 36.3%, the expenses attributed to
drugs 42.2% and the clinical consultations and
diagnostic tests 22.5%. In the study using the bot-
tom-up focus the hospital costs represented 43% of
the total, drugs 40% and consultations and comple-
mentary tests 17%.
Despite the differences observed in the absolute
values between the two types of studies, the distri-
bution of the costs was very similar. If the total
COPD direct cost is divided by the total Spanish
population, healthcare for COPD costs each citizen
$13.32 annually [65-67].
Scandinavia
The cost of COPD in Denmark amounts to 10% of
all healthcare costs. The annual cost of pharmaco-
logical treatment in Scandinavia is today around  
€100 per inhabitant. The cost in Denmark rose
from about €2 billion in 2004 to €3 billion in 2008
[68]. This huge cost is mainly covered by the public
health system, some private insurance and to a
minor degree by the patients themselves.
There are large differences between regions in the
prescribing pattern of drugs with the same effect
and side effect profiles but in some cases a 10-fold
difference in cost is reported. The general guidelines
for managing a disease entity are usually formulated
by scientific societies, and agreement about the
general use of medication by classes based on a
stepwise approach according to severity is usually
reached among specialists. A regulated practice has
developed by law for pharmaceutical substitution in
the pharmacy, i.e. the pharmacy shall deliver anoth-
er and cheaper medication to the patient than the
one written on the prescription form if the drugs
contain the same active substance in the same
amount and are used in the same way.
Each country has its own reimbursement system,
that comprises a common part which applies to
everybody and special rules for patients in specific
circumstances. In Denmark the first €115 spent for
the purchase of drugs is not reimbursed (however,
in the case of age < 18 years there is a 60% reim-
bursement also of this cost segment provided). The
% reimbursement increases gradually to 85% with
purchases above €400 in all age groups. However,
persons with chronic diseases pay up to a maxi-
mum of €450 out of their own pocket, and will
have all additional costs covered. In special cases it
is possible to apply for reimbursement of specific
drug treatments, and to have additional cost cover if
required by the personal economic situation, or
special support for terminal care and treatments.
A special group of people are the illegal immi-
grants, who have no public or private insurance and
have to face serious problems when falling ill. They
can in principle only be treated for acute severe dis-
ease and are then transported to their homeland as
soon as possible, whereas management of the cost
of chronic diseases is at their own total expense. 
Italy
The cost-of-illness for COPD in Italy was calculated
in 2002 from data collected by 28 Lung Units with-
in the framework of the National Health Service
(NHS). Mean cost/patient/year ranged from €1,500
to €3,912 according to the illness severity. Direct
costs, hospitalizations and emergency room (ER)
admissions, in particular, represented the main cost
driver [69]. Unacceptable levels for underdiagnosis
and mistreatment of COPD were also underlined in
that study. 
In a further investigation, the mean societal cost of
COPD was €1308/patient/year: as 75% of cost was
due to hospitalizations, a more effective strategy for
managing and controlling COPD exacerbations
was further strongly recommended in order to alle-
viate the burden of this disease in Italy [70].
When investigating the effectiveness of different
therapeutic interventions in terms of outcome opti-
mization, it was found that both a prompt diagnosis
of disease and exacerbations, together with an
appropriate long-term therapeutic approach, repre-
sent the most effective strategy to optimize all out-
comes related to the disease, and to substantially
reduce the impact of COPD on patient, healthcare
system and society [71].
In 2008, health resources consumption and costs
generated by COPD were calculated on a national
basis, in a real-life setting of 1-year duration, and
according to a bottom-up, observational, prospec-
tive multicentric study. At the end of the survey, out-
comes were compared with those of the previous
year [72]. A total of 748 patients were recruited,
and 561 were defined as eligible; the proportion of
moderate and severe COPD was 53.7% and 16.8%,
respectively. Mean total cost/p/y was €2,723.70,
ranging from €913 to €5,452 according to the dis-
ease severity. At the end of the survey, the demand
for health services had dropped significantly com-
pared to baseline: GP visits by 57.4%; ER use by
12.5%; hospitalizations by 18.4%. Furthermore,
even if direct costs remained the main driver of
cost, the mean total cost per patient dropped by
21.7% (p < 0.002), mainly due to a much more
appropriate interventional and therapeutic strategy.
When compared to previous studies, these data






























9 COPD doubled in a 5-year period in Italy: this trend
has been also registered in other countries (such as
USA) over the same period. Despite this, and
despite the fact that individual costs for COPD
exceed by 67.7% the mean per capita expenses of
the National Health System, appropriate treatment
for COPD does not seem to reach more than a lim-
ited 20% of patients.
Data from a recent cross-sectional study support the
evidence that also moderate COPD represents a
substantial economic burden for healthcare sys-
tems, and strongly indicate both the clinical and the
economic convenience of an earlier, long-term thera -
peutic intervention in these circumstances [73]. 
ROLE OF INSTITUTIONAL PLAYERS IN ITALY
The Italian NHS, National Health Service
In the 19th and first part of the 20th centuries, the
prevalent diseases were infections of an epidemic
nature (such as cholera, tuberculosis, poliomyelitis)
and the role of the state was in the first place to
guarantee drinkable water, sewage disposal and
improved conditions of life and in a second phase
to help protect the population through programs of
mass vaccination against disorders not being con-
trolled by the improvement in public hygiene. In the
last fifty years - following progress in medicine and
in the organization of the social state - Italy (as other
developed countries) has seen a radical change in
disease epidemiology and the main causes of death,
and this change has thrown the NHS into crisis.
As a matter of fact, the chronic invalidating disor-
ders that dominate the scene today cannot be man-
aged with the old hospital-centred model, based on
response to acute situations: the system has to be
readapted to the present epidemiological situation.
Today, diseases are linked to individual lifestyle
rather than to global living conditions, and hence
the role of the state is no longer to choose and
implement the best health options on behalf of citi-
zens but rather to help citizens themselves choose
the best options, through education, health informa-
tion and the provision of integrated services of pri-
mary, secondary and tertiary prevention.
The number of people affected by chronic broncho-
pulmonary disorders is predicted to rise substantial-
ly as the average age of the population increases. In
the absence of corrective measures, health costs
might more than double by 2050, becoming unsus-
tainable for the NHS. For this reason a radical
change in the organization of the NHS is deemed
necessary by political authorities, also in relation-
ship to the heavy crisis that has recently hit the
world economy. The future of the NHS will thus be
focused on primary prevention and early diagnosis
and rehabilitation (helping citizens to reduce the
invalidating consequences of diseases with the least
possible impact on the community).
These changes of the NHS will take place in the
context of an overall change in the whole welfare
system, centered on the idea that people first try to
develop their own resources to respond to their
needs, and live in a free and responsible manner,
actively participating in society. The new approach
to welfare must orient people towards active behav-
iour and responsible lifestyles, preventing situations
of need due to physiological events (infancy, mater-
nity, old age) or pathological events (disease, acci-
dent, disability) or to particular economic situations
(business or employment crises, unemployment,
end of work). In this context, health does not mean
simply 'treating the disease' but rather a priori pro-
moting wellbeing and developing personal abilities,
taking the different individual conditions into
account. The citizen’s active participation, a correct
information and health culture, a renewed relation-
ship of trust between family doctor and patient, are
the premises for promoting healthy life in the active
society.
Ministry of Health
The Ministry of Health must play a fundamental role
in the implementation of policies against cigarette
smoking, indoor and outdoor pollution, obesity,
and communicable diseases. Presently, these
actions are not well integrated, and this poor co -
ordination is an important limitation for the NHS.
Signs of the new importance now being attributed
to respiratory diseases are the fact that the Italian
National Health Plan 2006-2008 placed chronic
respiratory diseases among its four top health prior-
ities, and the Ministry of Health launched in 2009
GARD-Italy, the Italian counterpart of the Global
Alliance against Chronic Respiratory Diseases
(GARD) of the World Health Organization (WHO),
a voluntary alliance of national and international
organizations, institutions and agencies that has as
its goal to reduce the global burden of chronic res-
piratory diseases. The main objective of GARD-Italy
is to promote the development of a global chronic
respiratory disease program in Italy. Effective pre-
vention implies setting up a health policy with the
support of health care professionals and citizen
associations at the national, regional, and district
levels. What is required is a true inter-institutional
synergy: prevention of respiratory diseases cannot
and should not be the responsibility of physicians
alone, but must involve politicians/policymakers, as
well as the media, local institutions, school, and
food producers. GARD may represent a significant
experience and a great opportunity for Italy, and a
means to implement the GARD vision of a “world
where all people can breathe freely”.
Regional Health Services
The AGE.NA.S (National Agency for Regional
Health Services) has, among its activities, the task of
coordinating at national level the elaboration and
dissemination of clinical and organizational guide-
lines. The strategic use of guidelines allows to eval-
uate the quality of the services based on scientifi-
cally valid principles, recognized by operators and
decision makers alike. In fact, guidelines constitute
a primary source for the identification of indicators
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are also a means of communication among profes-
sionals and of information to citizens.
Guidelines have been criticized for how they rate
the quality of evidence and the strength of recom-
mendations, although with the development of sys-
tems such as GRADE (Grading of Recommendations,
Assessment, Development and Evaluation) this limit
has been partly overcome. Concerns now remain
about the need to elaborate ad-hoc initiatives for
the correct implementation of guidelines at national
and local (regional) levels. For several clinical con-
ditions, including COPD, limited information is
available about current practice versus standards of
management as recommended by the guidelines.
Significant deviations between current practice and
guidelines regarding the prescription and selection of
diagnosis and treatment options have been found for
COPD in Italy [6].
Alongside this comes the rational use of health
resources and the choice of diagnostic and thera-
peutic paths according to priorities which should be
established on the basis of the best available evi-
dence. Therefore, in the development of guidelines
all efforts must be addressed to the evaluation and
selection of interventions with a cost-effective profile.
Local health authorities and services
The actual setting in which the NHS changes
described above need to be planned and carried
out is the local district, i.e. it is here that the inte-
grated responses to people’s real and potential
needs are put into effect, where the social and
health services aimed at prevention, early diagnosis,
primary care, and home care have to be developed.
This means that, in the short term, a homogeneous
management of the social, health, and welfare serv-
ices must be achieved at the local level, in order to
create a continuum between systems of healthcare
and those for social protection. Such an integrated
management sees the social and health districts as
the citizens’ point of reference and the place where
this integration may occur effectively.
At organizational level, the health care for chronic
respiratory diseases, and COPD in particular, will
resemble that for other chronic disorders such as
diabetes. The goal is to increase the possibilities of
self management for the patient, and give more
responsibility to general practitioners (GPs), pro-
moting the use of telemedicine and home care. In
the specific field of pulmonology, the NHS must
undertake in each local health service [74]:
1. to prevent respiratory disease developing through
a substantial reduction of the number of smokers
in the community and strict control of risk factors;
2. to improve and anticipate diagnosis, in particular
for COPD and asthma, through a more wide-
spread use of spirometric tests and specialist
expertise;
3. to help patients to self manage their own disease,
through health education and pulmonary rehabil-
itation;
4. to integrate the care of patients affected by respi-
ratory diseases, by linking specialist care to pri-
mary care, and extending end of life treatment to
non-oncological conditions.
Particular mention must be made of pulmonary
rehabilitation: since the publication of national and
international recommendations there has been sig-
nificant progress in both techniques and outcome
measurement, not only for COPD but also for other
respiratory disorders [36]. Pulmonary rehabilitation
has been largely under-prescribed up to now [6] but
at present it is undergoing great development in
Italy, although not homogeneously throughout the
whole national territory. 
Role of the pulmonary specialist
Healthcare planning
An appropriate management of chronic respiratory
diseases, based on solid epidemiological data,
requires today a global approach defining the best
care for the patient throughout the entire course of
the disease, and in a sustainable way for the com-
munity. Numerous initiatives and studies are under
way everywhere. One of these is the Global
Alliance against chronic Respiratory Diseases
(GARD), an ensemble of national and international
organizations guided and coordinated by the World
Health Organization (WHO). The role of the pul-
monary specialist at global and national level has
been delineated within the context of GARD’s
strategies and corresponding actions [75]. 
In Italy, the Ministry of Health – which defined
chronic respiratory disorders as a priority of the
national Health Program 2006-2008 and hence
finalized, with the National Agency for Regional
Healthcare Services (AGE.NA.S), national guide-
lines for COPD – launched in 2009 GARD-Italy
[76].
Respiratory specialists are involved in the “central”
planning phase of all these initiatives, while other
specialists play a role in the “peripheral” phase of
implementation. Further on, these same specialists
will verify the applicability in the real world and the
final efficacy of what has been planned and imple-
mented. 
Implementing healthcare strategies
Patients affected by chronic pulmonary disorders are
at present managed in a discontinuous and non inte-
grated mode with inappropriate care procedures.
Prevention, too, is neither systematized nor inte-
grated. Inappropriateness costs both the individual
and the community. It has been calculated that GBP
£1.3 billion are spent each year in the U.K. for
Emergency Care admissions (3-4 visits per patient)
for a series of 18 diseases, COPD being at the top of
the list and asthma in third place. Varying percent-
ages of these visits resulted inappropriate at a retro-
spective analysis [77]. An optimal management of
chronic diseases would simultaneously prevent the
crowding of Emergency Care facilities, and improve
the global healthcare costs and the quality of life of
those affected.
The long-term goal must be to reduce the incidence






























9 prevention, while in the shorter term the target is to
reduce - in an economically sustainable way – the
social and economic burden generated by those
already affected, through more appropriate disease
management. 
The specialist has a definite role to play in primary
prevention, early diagnosis and rehabilitation, as
guide or coordinator or consultant depending on
the type of intervention, in close cooperation with
primary care physicians, other health professionals,
and patient associations. In concrete terms, the spe-
cialist will build up a network in which the
Operational Unit functions as the junction for the
whole course of respiratory care, from primary pre-
vention to palliative care, according to the follow-
ing scheme of action:
- in primary prevention: implement smoking ces-
sation, increase the opportunities for screening
for COPD and associated conditions;
- in secondary prevention: increase accessibility to
lung function assessment, experiment screening
models for associated conditions, e.g. lung can-
cer;
- in improvement of patient management: further
reduce hospitalization through integration with
services available in the local community, e.g.
home hospitalization, monitoring of patients with
chronic respiratory failure, health education,
telemedicine; test a model of pulmonary rehabil-
itation provided in the local territory; expand and
rationalize semi-intensive treatment; promote the
extension of palliative care to patients with
severe respiratory failure.
Healthcare planning for respiratory diseases must
reappraise its whole “mission” and reorganize the
specialist network based on a redefinition of the
role of the specialist. Having as a main target the
need to promote health rather than treat a disease
and to shift in-hospital to out-hospital care in a
patient-centered vision, the goal in practical terms
is to achieve greater possibilities of self-manage-
ment for the patient, greater involvement of primary
caregivers, through use of telemedicine, optimal
exacerbation management, and more options for
dedicated and planned home care. 
The model for the hospital pulmonary unit is analo-
gous to that of modern cardiology (i.e. intensive
management of the acute episodes in the hospital)
while the model for the local community is similar
to the one existing for the services of diabetology
(i.e. specialist consultation and guidance) with par-
ticular focus on self-management and pulmonary
rehabilitation for patients with respiratory failure.
The hospital specialist, who needs to be integrated
in a Specialist Unit in order to have full knowledge
of all the aspects, maintains the direct management
of emergencies. For this the Pulmonology Unit must
be an integral part of Intensive care and not part of
the medical ward, and its role in activities of non
invasive respiratory intensive care needs to be rec-
ognized and promoted.
There is evidence that information and communica-
tion technologies (ICT) can play an enabling role
over the whole range of services, from life-style and
self-management of health to improving health
related quality of life of patients as well as manag-
ing chronic disease conditions [78]. Properly
designed innovative health services supported by
ICT could have a positive impact on chronic disease
modulation and prognosis, shifting resources from
traditional acute care to integrated long-term home
care, focusing on early diagnosis and prevention of
exacerbations.
Despite the many advances and acknowledged
potential of technology, ICT adoption in healthcare
has lagged behind the scene. The barriers to ICT
originate at different levels and are associated to a
series of technological, cultural, legal, and market
related factors. Adoption of ICT in healthcare is cur-
rently a major priority in Europe as shown by the
major e-health deployment initiatives (e.g. epSOS)
launched through the Competitiveness and
Information Framework Program [79].
Role of the general practitioner (GP)
In a reformed NHS, one will need to go beyond the
concept of “integration” between hospital and local
territory in favour of a new interdisciplinary and
inter-professional approach placing the person at
the centre of the management process (which must
flow without discontinuity). In this vision, the hos-
pital will return to its “historical” role as a provider
of emergency and acute care while the general
practitioner, no longer operating “in isolation” but
in a collaborative network in association with other
professionals, will be the patient’s first reference
point for any health problem and the real case-man-
ager throughout the whole course of a disease
requiring complex interventions. The use of a per-
sonal electronic dossier containing all relevant
information about the patient is now adopted by
many GPs in Italy and is an extremely useful tool,
but it should become a general standard nation-
wide, shared by all professionals involved.
Due to its increasing prevalence, COPD is consid-
ered a social disease which necessitates special
attention at primary care level. 
GPs have a central role in disease prevention,
detection, treatment, and management. Smoking
cessation intervention is the cornerstone for pre-
venting COPD: the offer of brief advice by the GP
to every smoker who visits the GP’s office is
becoming a rule, as well as GPs’ growing aware-
ness of belonging to the wider network of anti-
smoking services. The manifold contacts on a year-
ly basis with their patients who smoke allow GPs
to carry out early detection by means of spiro -
metry, and to collaborate with pulmonologists if
needed. COPD treatment should be based on reg-
ular therapy with inhaled drugs (long-acting bron-
chodilators and steroids) to ensure a good quality
of life. 
Prevention and treatment of exacerbations is of the
utmost importance: avoiding airborne pollutants
(environmental tobacco smoke and urban pollu-
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exacerbation, and starting oral steroids and anti -
biotics courses, are the cornerstone of good prac-
tice by GPs. Finally, COPD management must be
based on planning regular clinical and functional
follow up.
Role of patients’ associations
The right to health, as defined in the Italian
Republic’s Constitution, is one of the fundamental
rights of an individual. The search for a different,
new balance in which it is the individual, and not
the disease, at the centre of the system, requires a
greater responsibility on the part of all the players
involved - including the patient - with the aim of
preventing or delaying the development of compli-
cations.
Interventions must be coordinated among scientific
societies, professional associations, volunteer
organisations, and public and private institutions.
It is then necessary to develop profiles for care
based on a multidisciplinary approach and ensure
continuity among actions for prevention, cure and
rehabilitation, with inter-sectorial interventions,
both medical and social, involving the family and
the volunteer organisations.
In the approach to chronic diseases in general, and
to COPD in particular, we must work to empower
the people, i.e. enable subjects to participate
actively in the therapeutic choices and in the deci-
sional process aimed at improving quality of life
and preventing complications.
Patients must be helped to acquire “ability” through
a better knowledge of the disease and treatments
available. Indeed, knowledge is essential to obtain
a good level of healthcare with the patient placed at
its centre. On the other hand, it is also necessary
that the healthcare system and social services
become aware of people’s needs, and are able to
work together to trigger a process of improvement,
in respect of the individual’s rights and freedom.
To conclude, we are all confident that new studies
on the pathogenesis, pathophysiology, and pharma-
cology of COPD will give us new insight into how
best to classify and treat at clinical level what likely
is a set of different disorders with the same label. At
the same time, it is not out of place to reiterate that
the real challenge for achieving an appropriate
approach to COPD - from both the individual’s and
society’s point of view - is to effectuate a conceptu-
al revolution in the context of long-term healthcare,
in the sense that a patient-tailored attitude must pre-
vail over the old concept of a rigid health system
offering a very limited range of solutions to different
problems. Such a change has started, but we are
still far from reaching a satisfactory set of minimal
recommended standards [80]. There is wide oppor-
tunity for quality improvement and the scientific
societies of pulmonary specialists can play a pivotal
role in implementing recommendations and devel-
oping research for reliable performance measures
that are necessary in the search for efficacy, efficien-
cy and equity in the management of COPD as of all
other chronic disorders.
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